Skip to main
REPL

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group Inc has significantly raised its probability of approval for the RP1 + Opdivo combination in anti-PD1 failed melanoma patients to 85%, up from 50%, supported by promising trial results. The safety profile of RP1 + Opdivo is favorable, with only 12.8% of patients experiencing grade 3 or higher treatment-related adverse events, indicating a potential for successful market entry. This positive outlook is further bolstered by the overall encouraging data from the IGNYTE trial, which may enhance the company's positioning within the biotechnology sector.

Bears say

Replimune Group Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from its inability to produce compelling efficacy and safety data for its lead product candidate, RP1, in future clinical trials. The company has encountered setbacks related to regulatory approvals, including a Complete Response Letter (CRL) from the FDA highlighting deficiencies in the clinical trial design and data quality of the IGNYTE trial. Additionally, there is a looming risk of medium- to long-term dilution due to potential financial needs, further complicating the company's path toward delivering on its pipeline of oncolytic virus candidates.

REPL has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 8 analysts, REPL has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.